Pages
Products
ChAT-GFP Lentivirus

ChAT-GFP Lentivirus

Cat.No. :  LV00984Z

Titer: ≥1*10^7 TU/mL / ≥1*10^8 TU/mL / ≥1*10^9 TU/mL Size: 100 ul/500 ul/1 mL

Storage:  -80℃ Shipping:  Frozen on dry ice

Inquire for Price

Lentivirus Particle Information

Quality Control

Cat. No. LV00984Z
Description This lentivirus contains GFP under the control of human ChAT (Choline O-Acetyltransferase) promoter.
Target Gene EGFP
Titer Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc.
Size Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

With the in-depth study of lentiviral vectors, the optimization of lentiviral vectors is also being explored to improve the safety of lentivirus in clinical use. The development of lentiviral vectors has gone through three stages. The first generation of lentiviral vector system is represented by the three-plasmid system. During the construction, the cis-acting elements required for packaging, reverse transcription and integration in the HIV-1 genome are separated from the sequences encoding trans-acting proteins and constructed on three plasmid expression systems, namely packaging plasmid, envelope plasmid and vector plasmid. Under the action of the cytomegalovirus (CMV) promoter, the packaging plasmid controls the expression of all viral structural genes except env; the envelope plasmid encodes the G glycoprotein of vesicular stomatitis virus (VSV); and the vector plasmid contains the target gene. These three plasmids are co-transfected into packaging cells such as human embryonic kidney 293T cells, and lentiviral particles with only one infection ability but no replication ability can be harvested in the cell supernatant. The first generation of lentiviral vector system is characterized by the fact that when constructing three packaging plasmids, in order to reduce the possibility of producing replication-competent viruses, the homologous sequences between the three plasmids are reduced as much as possible, but the packaging plasmids still retain the accessory genes of HIV. The second generation of lentiviral vector system is an improvement on the first generation, and all the accessory genes of HIV are deleted in the packaging plasmid. The removal of these accessory genes does not affect the titer and infectivity of the virus, and at the same time increases the safety of the vector. The third generation of lentiviral vector system adds two more safety features: one is to construct a self-inactivated lentiviral vector, that is, the 3′LTR of the U3 region is deleted, so that the vector loses the HIV-1 enhancer and promoter sequence, and RNA cannot be transcribed even if all viral proteins are present; the second is to remove the tat gene and replace it with a heterologous promoter sequence, so that only 3 of the 9 lentiviral vectors in the original HIV genome are retained (gag, pol and rev). Therefore, the third generation of lentiviral vector system is safer.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Versatile

This lentivirus vector was easily adaptable to various cell lines and experimental setups. Its versatility provided me with a reliable tool for exploring multiple research avenues.

Germany

02/09/2020

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction